Hypoxia and tumor metabolism in radiation oncology: Targets visualized by positron emission tomography

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 3, 2013, Pages 244-256

  Wijsman, R ^a   Kaanders, J H A M ^a   Oyen, W J G ^a   Bussink, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell hypoxia; Neoplasms; Positron emission tomography; Radiotherapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; CARBOGEN; CISPLATIN; DIACETYL (N4 METHYLTHIOSEMICARBAZONE) CU 64; FLORTANIDAZOLE F 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETHYLTYROSINE F 18; METHIONINE C 11; NICOTINAMIDE; NIMORAZOLE; PLACEBO; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TIRAPAZAMINE; UNCLASSIFIED DRUG;

AUTORADIOGRAPHY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CELL HYPOXIA; CELL METABOLISM; CHEMORADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; GLIOBLASTOMA; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; LARYNX CARCINOMA; LUNG NON SMALL CELL CANCER; METABOLIC RATE; MOLECULAR IMAGING; PHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE CANCER; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE;

ANIMALS; CELL HYPOXIA; HUMANS; MOLECULAR IMAGING; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, IMAGE-GUIDED; TUMOR MICROENVIRONMENT;

EID: 84888807237     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
2. Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010:CD002026.
3. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-5. (Pubitemid 27303621)
4. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACHNC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
5. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46. (Pubitemid 28109172)
6. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25:4066-74. (Pubitemid 47492951)
7. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37. (Pubitemid 35446742)
8. Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 2012;35:745-63.
9. Gwyther SJ. Modern techniques in radiological imaging related to oncology. Ann Oncol 1994;5 Suppl 4:3-7.
10. Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 2009;50 Suppl 1:106S-21S.
11. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol 2011;38:55-69.
12. Horsman MR, Wouters BG, Joiner MC, Overgaard J. The oxygen effect and fractionated radiotherapy. In: Joiner M, van der Kogel A, editors. Basic clinical radiobiology. Fourth edition. London: Edward Arnold; 2009. p. 207-16.
13. Magagnin MG, Koritzinsky M, Wouters BG. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist Updat 2006;9:185-97. (Pubitemid 44781210)
14. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
15. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-6. (Pubitemid 9239867)
16. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor, Cancer Res 2006;66:2219-23.
17. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized 02 tension measurements. Cancer Res 1991;51:3316-22.
18. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011;11:167.
19. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9. (Pubitemid 27318643)
20. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24. (Pubitemid 41503384)
21. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15. (Pubitemid 26330463)
22. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5. (Pubitemid 32448504)
23. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32.
24. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74. (Pubitemid 35424102)
25. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012;30:1777-83.
26. Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008;2:41-53.
27. Toustrup K, Sorensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22:119-27.
28. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59-67. (Pubitemid 36109716)
29. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish H et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6:757-64. (Pubitemid 41430716)
30. Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res 2012;18:301-7.
31. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80.
32. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S-48S. (Pubitemid 351948041)
33. Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-54. (Pubitemid 40065524)
34. Troost EG, Laverman P, Philippens ME, Lok J, van der Kogel AJ, Oyen WJ et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008;35:1803-11.
35. Bussink J, van Herpen CM, Kaanders JH, Oyen WJ. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010;11:661-9.
36. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104. (Pubitemid 46622121)
37. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006;80:151-6. (Pubitemid 44301544)
38. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60. (Pubitemid 43073432)
39. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;75:101-8.
40. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8.
41. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169-87. (Pubitemid 40326567)
42. Busk M, Horsman MR, Jakobsen S, Hansen KV, Bussink J, van der Kogel A et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009;92:429-36.
43. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F] Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317-26.
44. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13. (Pubitemid 43086004)
45. Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 2008;70:1202-12. (Pubitemid 351296127)
46. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]- fluoroarabinofuranosyl)-2-nitroimidazole(18F-FAZA). Eur J Nucl Med Mol Imaging 2009;36:1565-73.
47. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA - first small animal PET results. J Pharm Pharm Sci 2007;10:203-11.
48. Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-20. (Pubitemid 38461566)
49. Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011;108:14620-5.
50. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. (1)(8) F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (l)(8)F-FMISO. Nucl Med Commun 2012;33:1096-102.
51. Mahy P, De Bast M, de Groot T, Cheguillaume A, Gillart J, Haustermans K et al. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. Radiother Oncol 2008;89:353-60.
52. Dubois L, Landuyt W, Cloetens L, Bol A, Bormans G, Haustermans K et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009;36:209-18.
53. Mahy P, Geets X, Lonneux M, Leveque P, Christian N, De Bast M et al. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008;35:1282-9.
54. Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66. (Pubitemid 36686845)
55. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.
56. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000;41:327-36. (Pubitemid 30091355)
57. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177-83. (Pubitemid 29044189)
58. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006;47:989-98. (Pubitemid 46939952)
59. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-502.
60. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008;49:201-5. (Pubitemid 351225657)
61. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50. (Pubitemid 36734203)
62. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008;51:1641-8.
63. Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ et al. 18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. J Nucl Med 2013;54:532-40.
64. Crippa F, Alessi A, Serafini GL. PET with radiolabeled aminoacid. Q J Nucl Med Mol Imaging 2012;56:151-62.
65. Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J et al. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer 2011;129:870-8.
66. Yang TJ, Haimovitz-Friedman A, Verheij M. Anticancer therapy and apoptosis imaging. Exp Oncol 2012;34:269-76.
67. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the TransTasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005;23:79-87. (Pubitemid 41702625)
68. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02 02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
69. Gregoire V, Jeraj R, Lee JA, O'Sullivan B. Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive? Lancet Oncol 2012;13:e292-300.
70. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42. (Pubitemid 350251048)
71. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. IntJ Radiat Oncol Biol Phys 2008;70:1219-28. (Pubitemid 351296122)
72. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K et al. High Reproducibility of Tumor Hypoxia Evaluated by 18F-Fluoromisonidazole PET for Head and Neck Cancer. J Nucl Med 2013;54:201-7.
73. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2013;40:186-97.
74. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:541-51. (Pubitemid 47380112)
75. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008;70:2-13. (Pubitemid 350251039)
76. Choi W, Lee SW, Park SH, Ryu JS, Oh SJ, Im KC et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol 2010;97:176-82.
77. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011;101:369-75.
78. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82. (Pubitemid 32184623)
79. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. (Pubitemid 351355215)
80. Porter JR. Louis PASTEUR; achievements and disappointments, 1861. Bacteriol Rev 1961;25:389-403.
81. Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography-a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-37.
82. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52. (Pubitemid 38445681)
83. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M et al. FDG - a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006;33:1426-31. (Pubitemid 44885408)
84. Christian N, Deheneffe S, Bol A, De Bast M, Labar D, Lee JA et al. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol 2010;97:183-8.
85. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008;35:2294-303.
86. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
87. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012;39:27-38.
88. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer 2012;13:52-8.
89. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41. (Pubitemid 40981834)
90. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med 2012;53:1506-13.
91. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010;17:115-22.
92. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009;50:88-99.
93. Hentschel M, Appold S, Schreiber A, Abolmaali N, Abramyuk A, Dorr W et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2011;38:1203-11.
94. Schinagl DA, Span PN, Oyen WJ, Kaanders JH. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 2011;38:1449-58.
95. van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 2007;82:145-52.
96. Usmanij EA, de Geus-Oei LF, Troost EGC, Peters-Bax L, van der Heijden EHFM, Kaanders JHAM et al. 18F-FDG-PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer treated with Concomitant Chemo-Radiotherapy. J Nucl Med 2013; in press.
97. Sun W, Xu J, Hu W, Zhang Z, Shen W. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer. Colorectal Dis 2013.
98. Cuenca X, Hennequin C, Hindie E, Rivera S, Vercellino L, Baruch-Hennequin V et al. Evaluation of early response to concomitant chemoradiotherapy by interim (18)F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas. Eur J Nucl Med Mol Imaging 2013.
99. Zucchini G, Quercia S, Zamagni C, Santini D, Taffurelli M, Fanti S et al. Potential utility of early metabolic response by (18)F-2-fluoro-2-deoxy-d- glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy. Eur J Cancer 2013.
100. Bjurberg M, Kjellen E, Ohlsson T, Bendahl PO, Brun E. Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer. Int J Gynecol Cancer 2009;19:1600-5.